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Preliminary Details of a Light Ion Facility for Hadron Therapy and Research 
 
By J.W. Boldeman, R. Banati, H. Buttner, D. Cohen and R.F Garrett 
 
Abstract 
A proposal is being prepared for the construction of high-performance accelerator complex 
for radiation therapy and research. The accelerator will be capable of producing proton 
beams between 60 and 250 MeV and carbon beams with energies variable form 120 – 430 
MeV/amu. This paper presents some of the background material supporting the proposal. Also 
included are some of the preliminary technical details of the accelerator complex and the 
transfer beam lines to the various treatment locations and experimental stations 
 
1. Introduction 
 
Australia has few landmark scientific research facilities in comparison with similar and 
even some smaller G20 countries. Current landmark facilities include the Australian 
Synchrotron, the research reactor, OPAL, and several radio telescopes. One landmark 
facility which is being introduced in many countries is a High Energy Light Ion Facility 
for Hadron Therapy and Research.  
Cancer is a major burden on the Australian community - 1 in 3 men and 1 in 4 women in 
Australia will be directly affected by cancer during their lives. In 2005 for the very first time, 
the number of new cancer cases reported exceeded 100,000.  The following year, it was 
estimated that there were 106,000 new cases of cancer diagnosed in Australia (60,600 males 
and 45,400 females). Cancer is the leading cause of death in Australia with over 36,000 
people succumbing each year, in spite of a 30 percent improvement in survival over the last 
two decades. Cancers most commonly causing death are lung, prostate and colorectal in males 
and breast, lung and colorectal in women. 
Although there are many kinds of cancer affecting different organs in the body, they all are 
caused by uncontrolled growth of abnormal cells. In a healthy individual, cells grow, divide, 
and die in a highly regulated fashion.  During childhood, healthy cells grow and divide very 
rapidly until the individual becomes an adult.  At this stage, cell growth slows until in most 
parts of the body, cells only divide to replace worn-out or dying cells and repair injuries. 
Cancer cells often travel to other parts of the body where they begin to grow and replace 
normal tissue. This process, called metastasis, occurs when cancer cells find their way into the 
bloodstream or lymphatic system of our body.   
Cancer can be considered in two classes from the viewpoint of attempting to treat the patient 
• Generalized cancer where the cancer has spread from the original infested area to 
other parts of the body 
• Localised Tumours. 
Based on European Union data, the proportion of generalised cancers, when detected, 
constitutes about 42% of all cases. Of these, the mortality rate is about 88%. The two 
treatment regimes are surgery and chemotherapy although radiotherapy has value for 
palliative care. The remaining 58% comprise localized tumours where a variety of treatment 
regimes including surgery, chemotherapy and radiation treatment result in prolonging patient 
life by more than 5 years in 57% of cases. However, the morbidity is still very high and 
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patient outcomes even with survival often leave the patient with some unpleasant physical 
consequences. 
Improvements in radiotherapy over the last 20 years or so have contributed to increased 
survival but clearly there needs to be a major advance in treatment methods. Hadron Therapy 
(with protons, carbon ions) fills this gap and a large number of centres have been built in 
recent years or are under construction. Already more than 70,000 patients world-wide have 
been treated using this new method. Appendix I from reference 1 lists facilities currently in 
operation and their patient numbers to 2007. Also included in Appendix I is a list of new 
centres either under construction or in advanced planning.  
The physical advantages that ion beams have over X-ray (photon) beams was first pointed out 
in 1946 by Robert Wilson (2) although this had little impact on the medical community at the 
time. The first application of charged-particle beams took place at Lawrence Berkeley in 1954 
and, after a long period of low-level investment, major development of the technique began 
with the installation of dedicated hospital facilities at Loma Linda and Massachusetts General 
Hospital. 
The first proposal to construct an Australian Proton Therapy facility was prepared in May, 
2001 (3) as a discussion paper under the auspices of the Australian national Proton Facility 
Steering Committee. No specific facility was proposed and it was believed if support were 
achieved a commercial facility would be built at some unspecified location. Although the 
discussion paper solicited considerable interest no funding was obtained. The proponents 
continue to be active in promoting the technique.  
A subsequent attempt to seek funding for a combined carbon-proton facility was launched at 
the 15th Pacific Basin Conference on Nuclear Power (4). This led to the establishment of a 
committee seeking private investment funds however because of the global financial crisis the 
private investment disappeared. This proposal differed from the original in that it was 
proposed that the facility be constructed using Australian resources. This philosophy has been 
retained in this third proposal. 
Hadron Therapy facilities may be classified into three generations. The first generation 
comprises high energy nuclear physics facilities that have been adapted to provide beams for 
therapy. The second generation comprises specialist constructed facilities specifically for 
therapy purposes. These facilities are based entirely on the use of proton beams and are often 
sited in dedicated commercial operations. In recent years, research and treatment in Japan and 
in Germany have shown significant benefits for both proton and carbon beams.  This has led 
to the construction in Europe and Japan of high performance facilities providing both proton 
and carbon beams. This new class may loosely be described as third generation facilities.  
2. Physics Principles in Hadron Therapy 
Hadron Therapy is particularly suitable for the treatment of deep-seated tumours that are 
located near to critical organs and which respond poorly to conventional X-ray (photon) or 
electron radiotherapy. Because of the significantly reduced dose to healthy tissues during a 
typical treatment it is especially appropriate for tumours in children. In this expanding 
technology, beams of light nuclei (variously called in the literature light ions, hadrons but 
essentially either protons or carbon ions) are accelerated to very high energy and then used to 
target the specific tumour. Hadron Therapy is the modality of choice for the treatment of these 
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cancers because of the high level of control over the ion beam and because of the favourable 
ionisation distribution in the path length of that beam, in effect, the tumour killing capability 
of the ion beams. These qualities give hadron beams a fundamental edge over the best 
examples of conventional X-ray radiation treatment (5 - 9). 
 
2.1 Interaction Rate 
The value of hadron beams in radiation therapy can be readily understood by considering the 
underlying physics of the interaction of various types of particles with human tissue. The best 
technology currently available in Australia utilises X-rays (photons). Photons which is the 
generalized word to describe electromagnetic radiation i.e. X-rays, gamma rays, 
bremsstrahlung, interact with matter via three processes, Photoelectric effect, Compton 
scattering and Pair production. In principle each photon interacts only once with the 
components of the body and accordingly the intensity of the photon beam decreases as it 
enters the body. Therefore the dose deposited in the human body has an exponential term of 
the following form; 
I = Io e-μx         (1) 
Thus, the maximum dose is delivered to the near surface of the body where there are healthy 
cells, there is no finite range to the dose distribution and the dose continues past the tumour 
being treated. Furthermore, because of the effective negligible mass of the photon, there is a 
large angular deviation of the photon beam as it passes through the body. On the contrary, 
hadrons e.g. protons and carbon ions have a different interaction process, principally coulomb 
interaction with target electrons in the irradiated body. The dose rate is given by the following 
expression  
  dE/dx = (e4Z2effZ2N/mv2) * other terms.     (2) 
Simply, this means that a specific hadron ion gradually loses energy as it enters the body, 
slows down and finally stops altogether. At the end of its path it deposits a very large amount 
of energy as may be seen from the equation 2 above. This effect can readily be seen because 
of the term mv2 in the denominator which becomes asymptotically small as the energy or 
velocity of the particle decreases. This effect which is called the Bragg Peak has been known 
for more than 100 years and was first pointed out by the two Australian scientistsm, William 
Bragg and son. Furthermore, there is no radiation dose or energy loss after the ion has 
stopped. The key to the use of hadron beams is to adjust the energy of the hadrons so that they 
deposit their greatest energy in the tumour being targeted. The results of this difference in 
interaction are illustrated in Figure 1. The data for two ion beams, protons and carbon ions, 
and for traditional X-ray beams are shown. The dramatic increase in the radiation dose at the 
end of the carbon and proton pathways can be readily seen. Note that the doses in the figure 
are normalised to 1 at entry. 
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Figure 1  Normalised Relative Dose rates for X-rays, protons and carbon ions. 
 
2.2 Linear Energy Transfer 
Figure 2 shows the microscopic dose distributions for protons and carbon ions in water and 
DNA strand breakages for various energy ranges near the end of their tracks. 
 
Figure 2 Microscopic Dose Distributions for Protons and Carbon Ions (10) 
 
The dramatic increase in DNA double strand breakage observed with the carbon ions (right 
hand side of figure 2) shows that they are particularly useful in radiation resistant tumours. 
With single strand breakage, DNA has the ability to repair itself but with double strand 
breakage this is no longer possible. 
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2.3 Lateral Deviation of Hadron Beams 
A third important characteristic of the interaction of hadrons with human tissue is the lack of 
deviation of hadron beam from the original beam direction. Figure 4 from a presentation by 
Thomas Haberer (11 -12) shows the lateral scattering of three hadron beams as a function of 
depth in water. The lateral scattering is much less than that with photons and the degree of 
lateral scattering diminishes with atomic charge. 
 
 
Figure 3 Lateral Deviations of Proton, Helium and Carbon Beams in Water 
The value of all of these characteristics is revealed in Figure 4 taken from a presentation by 
Thomas Haberer (11). This shows the relative-dose distribution of a 4 mm wide 275 
MeV/amu C beam in water. 
 
Figure 4 Relative Dose Distribution of a 275 MeV/u C12 Beam in Water (11) 
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2.4 Summary 
  
The advantage that hadron therapy has over conventional radiotherapy can be summarized as 
follows. 
• In the treatment process, the dose to healthy cells is reduced by factors between 3 
and 10. This is particularly important in the treatment of children who have many years of life 
before them. 
• Because the hadron beams can be controlled by magnets and because of the small 
deviation of the hadron beam as it enters the human body it is possible to target tumours very 
close to critical organs. 
• It is possible to kill tumours that are resistant to normal electromagnetic radiation.  
• Hadron beams are more effective and the number of fractions (i.e. the number of 
times a patient needs to attend the facility) is reduced. 
• Side effects such as nausea are reduced. 
• With modern accelerator systems it is possible to use magnetically controlled 
pencil beams to radiate the detailed shape of the tumour. This is called raster scanning. 
 
2.5 Examples 
 
There are many examples in the literature of comparisons of dose distributions for hadron 
beams with those using the latest technology with X-rays(photons). Two examples are shown 
below. Medulloblastoma is a highly malignant primary brain tumour that originates in the 
cerebellum or posterior fossa. It is particularly invasive and rapidly growing tumour that, 
unlike most brain tumours, spread through the cerebrospinal fluid and frequently metastasize 
to different locations in the brain and spine. Treatment begins with surgery followed by 
radiation therapy. Medulloblastoma is a cancer which affects young children. Forty percent of 
all cases are diagnosed in children under 5. Figure 5 (ref 11,12) shows a comparison of the 
dose distributions with charged particles (hadrons) and with intensity-modulated photons 
(conventional radiotherapy). The aim of both treatment methods is to give a dose of 32 gray to 
the spinal fluid. The dominant feature from this figure is the remarkable difference in the dose 
to bone marrow, heart and intestines with charged particle (hadron) beams relative to the dose 
with conventional X-rays. While the dose to the healthy bone marrow, heart and intestines is 
almost negligible with charged particle beams (<1 gray), the dose in conventional 
radiotherapy to these organs is alarmingly high and almost equal to the dose to the cancerous 
spinal fluid. 
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Figure 5  A comparison of dose distributions for conventional and charged particle 
therapy of Medulloblastoma in young children 
 
Charged-particle beams are particularly suitable for cancers of the head and neck. Figure 6 
(ref 11,12) presents a comparative dose distribution for charged particle beams, in this case 
carbon beams and conventional X-rays for a tumour circled in purple in the head below the 
brain and behind the eyes. With charged particles it is possible to avoid any dose to the spinal 
cord while with conventional radiography considerable damage would be done to the spinal 
cord. The spinal cord in Figure 6 is outlined in green and it is noted that with Intensity 
Modulated photons there is a considerable unwanted dose to the spinal cord. 
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Figure 6 A comparison of dose distributions from carbon and intensity modulated 
radiotherapy of a tumour 
 
3. Patient Numbers 
 
Typically, the number of cancer patients in Australia who require radiation therapy is over 
40,000 per year. Presently, they are treated using various photon radiation facilities typically 
based on electron accelerators. While the treatment of almost all of these cases would benefit 
by the alternative use of protons or light ions, the proponents of Hadron Therapy facilities 
(e.g. 5) argue that approximately 15% of these would have a much better prognosis if ion 
therapy were used. In other words, approximately 6000 patients per year would have 
significantly better outcomes with ion therapy. Most of these would be treated with protons 
however a proportion of these cancers (typically 1200) are radiation resistant and carbon ions 
are necessary. 
 
As examples of the application overseas of hadron facilities the patient numbers for proton 
beams at the Lima Londa Hospital in the US (Appendix II) and carbon beams at National 
Institute of Radiological Sciences, Chiba, Japan (Appendix III) are presented. Recently, an 
assessment has been made of the proportion of those cases where hadron therapy has a 
significant benefit to the patients. The numbers given in Appendix IV are based on European 
Union data. It is believed from all of the arguments presented above that there is a compelling 
case to install a Hadron Therapy facility in Australia.  
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4. Scientific Applications of a Hadron Therapy Facility 
 
The second objective in the installation of a Hadron Therapy and Research facility follows 
from the many opportunities that such a facility would provide not only for ANSTO but also 
for the Australian research community in general. 
 
4.1 New Technologies 
 
The construction of the facility will in its own right introduce a great number of new 
technologies into Australia as has been seen with the construction of two pieces of scientific 
infrastructure, the OPAL research reactor and the Australian Synchrotron. 
 
The OPAL research reactor is a world-class neutron source which is presently equipped with 9 
high-performance beamlines providing a complete coverage of those areas of research where 
neutrons beams are the primary choice for the researcher. A full description of the capabilities 
is given in www.ansto/Bragg. 
 
The Australian Synchrotron is a world-class synchrotron facility currently equipped with 12 
beamlines that cover almost all aspects of research in material science, biology, 
crystallography etc. A full description is given in www.australian synchrotron/beamline. 
 
In addition to these major facilities there are a number of well developed tandem accelerators 
which focus on basic and applied science.  
 
Despite this investment, Australia seriously lags well behind comparable overseas countries in 
its provision of major research facilities, although in astronomy, Australia is well placed and 
has a critical range of facilities such that in this specific area Australia is able to attract foreign 
investment. This is not the case in accelerator facilities. 
 
It is important to point out the difference between the proposed facility and the Australian 
Synchrotron. In the proposed facility the accelerated particle is used directly in therapy and 
science. In the Australian Synchrotron, it is the secondary radiation from the electron beams 
that is used in the experimental systems. In operation the two facilities are quite different. The 
electron beams in the Australian Synchrotron are extremely relativistic whereas in the 
proposed facility the ions are only partly relativistic. The lifetimes of the electrons in the 
Australian Synchrotron are of the order of 20 hours whereas the ion beams are accelerated 
once and then used with, typically, a lifetime of 1 sec. The proposed facility is much more 
similar to the existing ion beam facilities currently operational on the ANSTO site. Therefore 
the two synchrotrons offer research opportunities in entirely different areas. 
 
The construction of the proposed facility is scheduled to take four years. At the conclusion of 
this process Australia would have 
• created an experienced accelerator community that now has the expertise to move to 
the next major initiative for Australia e.g. an Accelerator Driven System, energy recovery 
linac, 
• introduced a high level expertise in ultra- high vacuum technology,  
• established  a new generation of extremely advanced control engineers would have 
been established, 
• introduced an extended competence in magnet design, 
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• moved in a serious way into new and advanced detector design as a consequence of 
the requirements of the therapy facility 
• established an understanding of radio- frequency systems 
•  extended the understanding of ion source design 
•  created an energetic and visionary group of people ready for the next challenge. 
 
4.2 Radiobiological Research 
 
The proposed facility would revolutionise research in many areas particularly in the biological 
sciences because of its ability to produce a variety of very energetic particles previously 
unavailable in Australia. These include the following areas of research. 
•  The study of low-dose effects 
•  Radio Biological Effectiveness (late effects, genetic mutation, transformation) of high 
energy particles, 
•  Determination of radiosensitivity of different tumours and normal tissues and 
molecular correlates  
•  Detailed study of chromosome damage 
•  The importance of hypoxia 
•  interaction of ion therapy and chemotherapeutic agents 
•  integration of biologic data into biological modelling for treatment planning  
 
Clinical dosimetry for heavy ions is not at the same level of accuracy as dosimetry for 
conventional photon facilities (no primary standardization laboratory) and all of the above 
areas of research are of high priority. 
 
4.3 Clinical Research 
The proposed facility in its dual role of research and therapy will lead to substantial cross-
disciplinary research between radiobiologists, clinicians and physicists. It should be 
understood that this facility introduces Australia into a new area of activity where currently 
there is no stand alone solution and there is an overwhelming demand for a multidisciplinary 
team. ANSTO through its relationships with the universities and medical institutions is in an 
excellent position to marry these different areas into a cohesive research team. 
 
4.4 Basic Research 
In a number of areas of basic research the facility has the capability of extending Australian 
studies significantly. These areas include 
•  proton – neutron production cross-sections 
•  proton scattering cross-sections 
•  nuclear cross section measurements 
•  preliminary studies of ADS systems 
•  decay spectroscopy, gamma spectroscopy 
•  exotic beams and reactions. 
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4.5 Atomic Physics 
 
Atomic physics is an area where Australian scientists have an enviable reputation. The 
proposed facility will greatly extend their research opportunities and help them to maintain 
their current international reputation. Specific areas of operation include 
• spectroscopy and atomic properties of relativistic ion systems, 
• optical spectroscopy 
• Atomic Collision Process,  
• dielectric recombination measurements,   
• heavy- ion ionisation processes,  
• charge-state studies,  
• coulomb fragmentation in heavy ion collisions,  
• radiative electron capture studies.  
• heavy-ion stopping in matter. 
 
4.6 Detector Development 
 
The application of charged particle beams in therapy proposes extremely important questions 
for control and monitoring detector systems. Although therapy with hadron beams has been in 
progress for many years it would appear that the status of detector systems lags that in several 
other areas of research where Australia has previously developed a strong research presence. 
 
5. Procedures in the Construction of the Australian Hadron Research and Therapy 
Facility 
 
Hadron Therapy Facilities by their very nature involve sophisticated physics, engineering and 
medical expertise. Presently, there are no commercial organizations accepting orders for 
combined proton carbon facilities. Therefore if Australia is to take advantage of this advance 
in the treatment of cancers it will be necessary to construct one with Australian expertise. This 
of course has the advantage that the technology involved in construction will now be resident 
in Australia.  
 
To build the Australian Hadron Therapy Facility it is proposed to adopt the same principles of 
construction that have proved very successful in the past in Australia, particularly at the 
Australian Synchrotron. Thus, it is proposed that ANSTO and its partners will manage the 
project including the overall design of the facility. The project will be divided into a number 
of specific components and international suppliers will be contracted to supply these specific 
components. ANSTO will be responsible for the integration of all the components of a 
facility. ANSTO will also be responsible for commissioning the overall facility and its 
subsequent operation. Approximately 60% of the capital cost of the facility will be spent in 
Australia.  
 
To minimize the risk, a close relationship has been established with a number of leading 
laboratories overseas. CERN is generally regarded as the world’s leading research laboratory 
and has indicated that it is willing to advise on the project. Similarly, specialists from the Paul 
Scherrer Institute (Switzerland) have expressed an interest in helping. Preliminary steps have 
also been made to invite several other leading figures in accelerators and hadron therapy to 
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join the International Advisory Committee including specialists from Japan and the United 
States. 
 
5.1 Specifications of the Australian Hadron Therapy Facility 
 
It is proposed that the facility be based on a versatile synchrotron accelerator capable of 
producing high-energy ion beams of both protons and carbon with the potential to utilise ion 
species between these two and additional light ions up to oxygen. The energy of the beams to 
be extracted from the facility will be variable. The requirements for both ion beams include 
• Maximum penetration depth in the human body of approximately 32 cm 
• Minimum penetration depth of 3.5 cm 
• Sufficient current to provide 2 grays of radiation to a targeted tumour in about 2 –    
3  minutes. 
 
With these principal requirements the hadron beams must be variable in energy  
• 120 - 430 MeV/u for C12 beams and 
• 60 - 250 MeV for protons. 
 
Furthermore, a high degree of focus is required for the delivered beam plus a smooth 
deposition rate. The only accelerator facility capable of meeting all these requirements is a 
synchrotron.  
 
5.2 The Physics Design of the Australian Hadron Therapy Facility 
 
To minimize the risk, reduce the construction time substantially and install a state of the art 
facility it is proposed to adopt an established synchrotron design. To this end, a small team of 
specialists conducted a feasibility study of alternate options and established strong 
relationships with key European laboratories. 
 
 As part of its promotion of the wide scale capability of modern accelerator systems and in 
response to requests from its member states, in particular the TERA Foundation (TErapia con 
Radiozioni Adroriche), (13), the CERN laboratory prepared a detailed design, PIMMS (Proton 
Iobn Medical machine), (14), of a high-performance hadron facility which is available to its 
member states. ENLIGHT, the European Network for Research in Light-Ion Hadron Therapy 
was also established to coordinate a pan-European effort with a common multidisciplinary 
platform for using light ions for radiation therapy.  
 
This complete but generic design was adopted by the CNAO organization in Pavia (Italy), 
(Centre Nazionale di Adroterapia Oncologica), (15). While they utilized most of the PIMMS 
design they did make some small modifications as a result of the detailed engineering design. 
This facility has been constructed and is undergoing final commissioning at this time. 
 
A second group, MedAustron (Austria) (16), has adopted the CNAO revisions to the PIMMS 
design. In collaboration with the Accelerator Division of CERN they have also made some 
additional refinements. The latest revisions to the PIMMS design result in a very high 
performance facility with high flexibility and complete diagnostic instrumentation, which has 
been described as the Rolls Royce of Hadron Therapy facilities. It is proposed that the 
Australian Hadron Research and Therapy Facility be based on the MedAustron improvements 
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of the original PIMMS design. Negotiations have begun with the relevant partners to secure 
agreement with this suggestion and, if possible, to purchase the engineering drawings for the 
synchrotron itself. 
 
5.3 Details of the Accelerator Complex 
 
A full design study will be produced following approval for construction. This will be based 
on engineering drawings from the European partners with some specific requirements for 
Australian conditions and the chosen site. However, a great deal of preliminary work has been 
done. The original PIMMS layout of the synchrotron and associated facilities is shown in 
Figure 7. This was a generic design incorporating a host of alternative features that potential 
constructors could consider. 
 
Figure 7 Generic Design of the PIMMS Facility 
 
The principal elements of the PIMMS facility included 
• Separate proton and carbon ion sources 
• Two pre accelerators 
• Transport line to the synchrotron 
• Injection system into the synchrotron 
• Booster synchrotron 
• RF accelerator cavities 
• Diagnostics 
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• Power supplies 
• Vacuum system 
• Cooling 
• Extraction scheme using third order resonance extraction 
• Beam transport system to the radiation areas 
• Radiation areas 
• Control system 
• Safety 
• Buildings. 
 
As indicated previously, there have been some minor modifications of the original PIMMS 
design since it was first published in August 2000 and it is planned to incorporate these in an 
Australian facility.  
For the purposes of the subsequent discussion, it is appropriate to consider the technical 
complex in three separate areas. 
• Injection system 
• Synchrotron 
• Transport and radiation facilities. 
 
5.3.1 Injection System 
 
The injection system for the Heidelberg Ion Therapy (HIT) facility is shown in Figure 8 
(11.12). It is noteworthy that in this facility the two pre-accelerators in the original PIMMS 
design have now been replaced by a single pre-accelerator. It should also be pointed out that 
the design on the HIT injection system was conducted by GSI Darmstadt and is not based on 
PIMMS. The equipment here is extremely specialised and it is proposed to proceed as CNAO 
and MedAustron have done in tender action for a complete system. 
  
 
 
Figure 8 Injection System for the HIT facility - courtesy Thomas Haberer 
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The actual location of the injection system with respect to the synchrotron is open to debate. 
CNAO have located the entire injection system within the perimeter of the synchrotron. This 
choice certainly saves on space and to some extent on concrete shielding. However the region 
inside the synchrotron becomes very crowded and no work can be pursued on the injection 
system independently from work on the synchrotron. On the other hand, MedAustron are 
planning to locate the injection system outside the perimeter of the synchrotron. The location 
of the injection system will be determined primarily by the amount of space available on the 
selected site. 
 
The transfer line from the injection system to the synchrotron is relatively simple and could be 
included in the commercial injection system or constructed independently. This remains an 
open question at this time. 
 
The details of the actual injection system and the fill structure will follow the practise at HIH, 
CNAO and MedAustron. 
 
 
5.3.2 Synchrotron 
 
It is planned to construct the latest revised version of the PIMMS lattice.). The configuration 
of the accelerator component of the facility is shown in Figure 4, using the WinAgile Code 
(17), courtesy of M. Benedikt (CERN, MedAustron) (18) for the input file. The figure shows 
only the dipoles, quadrupoles and sextupoles of the latest revision. The input file provides 
complete data including diagnostics, correctors, RF, injection and extraction elements. 
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Grid size    3.0000 [m]
Horizontal plan view [X-Y plane]
 
 
Figure 9 Horizontal Configuration of the Synchrotron, courtesy M. Benedikt 
(CERN/MedAustron) – WinAgile Output 
 
The calculated Betatron functions for this lattice with Carbon 6+ ions at 400 MeV/amu are 
shown in Figure 10. 
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Betatron amplitude functions [m] versus distance [m]
Dispersion functions [m] versus distance [m]
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Figure 10 – Horizontal and Vertical Betatron Amplitude Functions plus Dispersion 
Functions – WinAgile Output. 
 
It will be noted that the circumference of the lattice is now 77.648 m. 
 
It is planned to use third-order resonance extraction as is used at HIT, CNAO and most other 
synchrotron facilities. The horizontal tune diagram for slow third order resonance extraction is 
shown in Figure 11. This is the condition of the lattice for slow extraction. The details of the 
extraction system, RF etc are not discussed in detail here. 
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Figure 11  Horizontal Tune Diagram showing the Horizontal Tune now shifted to the 
third order resonance at 1.6667. 
 
For the specified beam parameters, the 2σ beam envelopes are shown in Figure 12 for a 
horizontal emittance of 5 πmm mrad and a vertical emittance of 0.73 π mm mrad. 
 
Horizontal beam envelope [m] versus distance [m]
Vertical beam envelope [m] versus distance [m]
Note: Linear optics
 0.000
 0.000
77.648
77.648
 0.025000
 0.025000
-0.025000
-0.025000
Betatron envelope Momentum envelope
 
 
Figure 12  Beam Envelopes 
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Table 1 lists some relativistic data for the Carbon beam at 400 MeV/amu. 
 
Table 1 Illustrative Kinetic Parameters for the Synchrotron 
 
Particle 12 C 6+ 
Kinetic Energy 0.400 GeV/amu 
Average Momentum 0.952303 [GeV/c/u] 
Beta = v/c 0.714609 
Gamma = m/m0 1.42954 
Beta*gamma 1.02156 
Magnetic Rigidity 6.34641 Tm 
Revolution Time 0.362444 10-6 s 
 
6. Transfer and Transport Lines 
 
A comprehensive account of a potential configuration of the transport and transfer lines to the 
various treatment facilities has been given in the original PIMMS document (14). A more 
recent paper by M Benedikt (19) has expanded on some of the details. The principles 
expressed in these documents will be followed for the proposed Australian hadron Facility 
although there will be variations imposed by the site and the need to reduce the costs of the 
concrete. 
 
In essence, the transfer and transport lines may be subdivided into a number of specific sub- 
units as discussed in PIMMS. The subsets include 
• a matching section to match the extraction optics of the synchrotron to the continuing 
beamlines. 
• a sub-unit in which the variation on the horizontal and vertical size of the transported 
beam to the various irradiation facilities can be changed. This one subunit will act for 
all beamlines. 
• a second sub-unit to extend the beamline 
• specific beamlines to take the beams to horizontal irradiation positions, vertical ones or 
beamlines in rotating gantrys. 
In all of the subsequent discussion an effort has been made to reduce the number of 
independent components and to standardise on the dipole and quadrupole magnets as far as it 
is possible. For that reason all quadrupoles have the dimensions of the quadrupoles in the 
revised PIMMS synchrotron with effective field lengths of 360 mm. In addition the dipoles in 
the horizontal bending beam lines are identical with those in the synchrotron.  
 
 
6.1 Matching Section 
 
The matching section has been discussed in some detail in the original PIMMS paper. To 
provide an accurate assessment of the details of this section, the final components in the 
synchrotron lattice need to be modified in the computer input file essentially to account for the 
variations inherent in the extraction optics after tune horizontal tune has been moved to the 
third order resonance. This has been discussed in considerable detail in the original PIMMS 
design paper and the parameters presented there are adopted without discussion.  
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Essentially the matching section is required to provide optimum matching of the output optical 
parameters of the synchrotron beam (following third order resonance extraction) to a new set 
of convenient optical parameters that can serve as an optimum source for the following 
sequence of treatment and experimental facilities. 
 
The geometry of the matching section is shown in Figure 13. The first 15 parameters in the 
input file for the WinAgile calculation are taken directly from the PIMMS Machine Study. 
Table 2 lists the required matching optical parameters for the entry and exit points. 
 
Table 2 Entry and Exit Optical Parameters 
 
Parameter Entry Point Exit point 
Horizontal Beta βx 5.000 m 3.000 m 
Horizontal αx  0.00 
Vertical Beta βz 7.000 m 3.000 m 
Vertical αz  0.00 
Horizontal Dispersion ηx 2.00 m 0.000 m 
Derivative Horizontal Dispersion 0.00 0.000 m 
Vertical Dispersion ηz 0.00 m 0.000 m 
Derivative Vertical Dispersion 0.00 m 0.000 m 
 
 
 
Grid size    2.5000 [m]
Horizontal plan view [X-Y plane]
 
 
 
 
Figure 13 Configuration of the Matching Section – WinAgile Output 
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Betatron amplitude functions [m] versus distance [m]
Dispersion functions [m] versus distance [m]
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Figure 14 Betatron Functions – Matching Section 
 
This configuration is by no means final and is under review. It may be possible to replace the 
final three dipoles by two that are identical to the dipoles in the synchrotron. 
 
6.2 Beam Size Module 
 
Grid size    1.5000 [m]
Horizontal plan view [X-Y plane]
 
Figure 15 Six Quadrupoles of the Beam Size Module 
 
The beam size module comprises six standard quadrupoles. The objective here is to vary the 
vertical beta function from 3 m to at least 15 m to provide a variation in the vertical beam size 
at the treatment position. The horizontal beta function remains unchanged however variation 
in the horizontal beam size is achieved by phase variation. There is a detailed discussion in 
the original PIMMS design report. Figure 16 – 19 show the betafunctions for four different 
beam sizes. 
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Betatron amplitude functions [m] versus distance [m]
Dispersion functions [m] versus distance [m]
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Figure 16 Twiss parameters (optical parameters) for βz = 3 m 
 
Betatron amplitude functions [m] versus distance [m]
Dispersion functions [m] versus distance [m]
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Figure 17 Twiss Parameters for βz = 5 m 
 
Betatron amplitude functions [m] versus distance [m]
Dispersion functions [m] versus distance [m]
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Figure 18 Twiss Parameters for βz = 10 m 
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Betatron amplitude functions [m] versus distance [m]
Dispersion functions [m] versus distance [m]
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Figure 19 Twiss parameters for βz = 15 m 
 
6.3 Extension Module 
 
Following the philosophy of the PIMMS design, a symmetric module is required to transfer 
the beam from a specific location to the next delivery position. The seven quadrupoles to 
achieve this are shown in Figure 20 and the corresponding Twiss parameters for βz = 3 m are 
shown in Figure 21. 
Grid size    2.0000 [m]
Horizontal plan view [X-Y plane]
 
Figure 20  Extension Module 
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Betatron amplitude functions [m] versus distance [m]
Dispersion functions [m] versus distance [m]
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Figure 21  Twiss Parameters for Extension Module 
 
6.4 Horizontal Beamline Facility 
 
At this stage it is envisaged that the beam will be deflected through 0.78 radians (45 deg) to 
each of a number of  horizontal radiation treatment positions. The module to achieve this is 
based on two standard dipole magnets and seven standard quadrupoles. The extension of the 
beam to the actual treatment location has not been finalised at this time and depends on the 
configuration etc of the shielding and related building. The configuration of the Horizontal 
Beamline Facility is shown in Figure 22 and corresponding Twiss parameters in Figure 23. 
 
Grid size    1.5000 [m]
Horizontal plan view [X-Y plane]
 
Figure 22 Configuration of the Horizontal Beamline 
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Betatron amplitude functions [m] versus distance [m]
Dispersion functions [m] versus distance [m]
 0.000
 0.000
15.542
15.542
 25.0000
   1.0000
  -1.0000
Horizontal Vertical  
Figure 23  Twiss Parameters for the Horizontal Beamline 
 
6.5 Vertical Facility 
 
It is proposed at this time to have one treatment position with both horizontal and vertical 
beams. The design of the vertical beam requires very large dipole magnets. The configuration 
of the vertical beamline is shown in Figure 24 and the corresponding Twiss parameters in 
Figure 25. 
 
 
 Grid size    3.0000 [m]
Side elevation view [X-Z plane]
 
Figure 24  Vertical Beamline 
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Betatron amplitude functions [m] versus distance [m]
Dispersion functions [m] versus distance [m]
 0.000
 0.000
40.921
40.921
 35.0000
   9.0000
  -9.0000
Horizontal Vertical  
Figure 25 Twiss parameters Vertical Beamline 
 
7. Treatment Facilities 
 
As presented in Section 6, the various components of the transfer lines function as discrete 
modules. The philosophy is that these can be added together as desired. For example a specific 
configuration might be  
• matching module 
• beam size module which acts for all subsequent radiation positions 
• a horizontal beamline 
• with the dipoles magnets in the horizontal beamline switched off, an extension line 
would take the beam to the next treatment beamline. 
• the next takeoff could be for a second horizontal beamline or a vertical beamline. 
 
It is seen that the various designs are very flexible and can be fit together in a variety of 
configurations and the final configuration will be determined by the managers of the facility 
and the level of funding. At this time it is expected that well characterized ion beams would 
be supplied to 
• one or two horizontal proton-carbon beamlines  
• one combined horizontal and vertical beam carbon-proton radiation room 
• one radiation chair in its own room 
• one experimental station to develop new irradiation procedures and study new 
applications of high energy ion beams. 
 
In addition to the treatment facilities, there would also be a need for supporting facilities 
associated with the site. In particular the new PETNET centre at Ansto would be particularly 
valuable in providing a supporting role.  
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7.1 Associated Facilities 
 
The facility will need a number of supporting facilities to ensure that the most efficient use is 
made of it. The facility itself will have in the treatment rooms, where carbon beams are to be 
utilized, a PET camera to monitor in real time the location of the radiation dose. This is 
possible because through the interaction with human tissue, the carbon 12 beams produce a 
small quantity of  carbon 11 which is a well known PET isotope with a very short half life. 
 
In addition, there will be a need for reception areas, treatment preparation areas and 
consultation rooms. There is also a need for some local accommodation and this is already 
available via the Lucas Heights Motel. Since ANSTO is a major user laboratory, a range of 
services is available for the large group of external users who are conducting experiments on 
the ANSTO facilities. 
 
For the research activities proposed for the facility there is a need for a wide range of 
supporting scientific infrastructure. These include 
• major computing and software support 
• high technology engineering workshops 
• radiation and dosimetry services 
• electron microscopes 
• a full range of laboratory services including glove boxes, fume hoods etc 
• an animal laboratory including an animal pet camera 
• ion beam analysis services on the ANTARES and STAR accelerators 
• a deuteration facility 
• the neutron beam facilities on the OPAL reactor. 
 
7.2 Buildings 
 
The design of the building to house the Facility and its associated components has not been 
started. However preliminary drawings indicate that the space requirements for the accelerator 
system and the associated research and therapy rooms will require an area of approximately 
6000 m2. In addition, buildings for the associated activities will require an area of 
approximately 5000 m2. 
 
The actual location of the facility has not yet been determined. However there are a number of 
sites outside the security area of the present ANSTO laboratory that are under investigation. 
These areas are particularly attractive as there is a large rock shelf at Lucas Heights which 
would provide support for the heavy accelerator components and accordingly significantly 
reduce the costs. 
 
7.3 Construction Staff 
 
The staff requirements to construct the facility have been evaluated based on previous 
experience in the installation of the tandem accelerator, ANTARES, and the construction of 
the Australian synchrotron. A total of 120 man years is needed. The actual breakdown of the 
prospective staff numbers is given in Appendix V. These numbers assume that a full sized 
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carbon proton facility is to be constructed. The numbers are clearly dependent on the size of 
the final facility. 
 
8. Alternatives and Costs 
 
The cost of a hadron therapy facility including all of the capabilities listed above was 
evaluated in early 2008 based on costs extrapolated from costs incurred in building the 
Australian Synchrotron and information from international suppliers. These costs have been 
inflated to 2010 dollars and a budgetary figure of $180 M is believed to be more than adequate 
to produce a world class facility.  
 
This proposal is for a very-high-performance state-of-the-art hadron therapy facility providing 
world class performance and allowing the options of incorporating new technologies as the 
science advances. Its construction would also introduce a great range of new technologies and 
capabilities into Australia and provide a platform on which to build further landmark facilities 
in the future. Some consideration is given below to lesser performance alternatives. 
 
The alternatives include 
• Commercial cyclotron facility – protons only 
• Commercial synchrotron facility – protons only 
• Nationally constructed synchrotron facility – protons only. 
 
In evaluating the alternatives there is a number of over riding issues. The beamlines are to a 
large extent independent of the accelerator facility that drives them. So all of the options 
listed above would potentially be required for a commercially-based proton synchrotron and 
with some modification a cyclotron-based facility. Furthermore, the buildings which comprise 
a major component of the costs of a facility are not too different depending on the options. A 
combined carbon-proton synchrotron has a diameter of approximately 26 m versus a diameter 
of about 7 m for a proton synchrotron. Consequently, the footprint of a combined carbon- 
proton machine is about 20% larger. 
 
A preliminary assessment of the pros and cons of the alternative options is given below. 
 
Table 3 – Commercial Cyclotron – Protons only 
Pros Cons 
Low cost option 
Possible lower risk 
Slightly inferior performance relative to a 
synchrotron 
No flexibility 
Very limited research capability 
Very limited technology transfer 
Long term dependence on supplier organization
Therefore higher operational costs 
 
 
 
 
 
 
 
Table 4 – Commercial Synchrotron – Protons only 
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Pros Cons 
Low cost option – several million more 
than cyclotron 
Lower risk 
More control of beam than with a cyclotron 
Some flexibility but limited by the synchrotron
Limited research capability 
Some technology transfer 
Independence from the supplier 
 
Table 5 – Nationally Constructed Synchrotron – Protons only 
Pros Cons 
Potentially lowest cost of all 
Greater flexibility 
Good technology transfer 
Improved research capability 
Some risk 
Less options than carbon-proton machine 
 
 
It is expected that construction of any of the facility will take approximately 4 years with two 
years required to ramp up the performance of the facility to full operational capacity. The 
annual cost of operating of the facility has been estimated at $10 M/year. 
 
9. Advisory Committees 
 
In the planning and construction stage there will be a need to be a number of Advisory 
Committees. Appendix VI. 
 
10. Conclusion 
 
The risk involved in a national effort to install a hadron therapy facility has been substantially 
reduced because of the CERN study and the establishment of close relations with CERN and a 
number of other laboratories with considerable relevant experience. It is believed that Ansto 
and Australian science have the capabilities necessary to construct such a facility as other 
national groups have done. The construction of the Australian Synchrotron has been 
completed and incorporates many of the engineering features that are also needed for a hadron 
therapy facility. For the most part, specialist component manufacturers were contracted to 
provide items for which they were recognized as world leaders and activities on the 
synchrotron site were largely integration of the component parts.  
 
11. Acknowledgements 
 
The authors are particularly indebted to Thomas Haberer and Michael Benedikt who provided 
a great deal of extremely valuable data. We also acknowledge valuable information from 
Steve Myer, Hartmut Eichkoff, Lenny Rivkin and many other members of the staff at HIT, 
GSI, PSI and CERN. 
 
12. References 
 
1. Jean-Michel Lagniel, PAC-07, Alberqueque, New Mexico, MOZBC02, page 127. 
2. R. R. Wilson (1946), Radiological Use of fast Neutrons, Radiology, 47, p 487. 
3. Australian National Proton Facility, Discussion Paper, May 2001, Australian National 
Proton Facility Steering Committee. 
 31
4. J. W. Boldeman, An Entry Level Hadron Therapy Facility, 15th Pacific Basin 
Conference, Sydney 2006. 
5. U. Amaldi (2001), Hadrontherapy in the world, Impact and Applications of Nuclear 
Physics, NUPECC.org/iai 2001/report/B32.pdf. 
6. W. T. Chu, B. A. Ludewigt and T. R. Renner, Instrumentation for Treatment of 
Cancer using   Proton and Light-Ion Beams, Rev. Sci. Instrum. 64(8), August 1993. 
7. G. Kraft, Tumor Therapy with Heavy Charged Particles, Progress in Particle and 
Nuclear Physics 45 (2000), 473 – 544. 
8. M. Regler, M. Benedikt and K. Poljanc, Medical Accelerators for Hadrontherapy with 
Proton and Carbon Ions, Hephy-Pub-757/02. 
9. U. Amaldi, Conformal radiation therapy with hadron beams and the program of the 
TERA Foundation, Rays, (1998), Jul – Sept; 23 (3) pages 486 – 507. 
10. M. Kramer, GSI, Darmstadt. 
11. Thomas Harberer, Heidelberg Ion Therapy Center, Hadron Therapy Workshop, Erice 
2009. 
12. Thomas Haberer Heidelberg Ion Therapy Center, Particle Beam Production – A 
Synchrotron-Based System, PTCOG 2009. 
13. U. Amaldi and M. Silari (editors), The TERA-project and the Centre for Oncological 
Hadrontherapy (second edition 1995). 
14. Ph. Bryant et al., Proton-Ion Medical machine Study (PIMMS), Part 1, CERN-PS-
1999-010, and Part II, 2000-007. 
15. Sandro Rossi, CNAO Foundation, Radiotherapy Hadrons: new devices..  
16. R. Potter, T. Auberger and M. Regler, Med-AUTRON – Ein Osterreichisches 
Krebsforschung-und Behandlungszentrum zur Hadrontherapie in Europa, Machbarkeiststudie, 
1998. 
17. M. Benedikt: Optical Design of a Synchrotron with Optimisation of Slow Extraction 
for Dadron Therapy, Thesis, TU-Wien (1997).  
18. Ph. Bryant, Agile program for synchrotron lattice design, http://www.cern.ch/-bryant  
 32
 Appendix I   PARTICLE THERAPY FACILITIES IN OPERATION (PTCoG) 
 
 
Year Proton(P)/ 
Carbon (ion) 
Facility Location No of People 
1961 P Harvard Boston, USA 9116 
1969 P ITEP  Moscow, Russia 3927 
1975 P  St Petersburg, Russia 1320 
1979 P  Chiba, Japan 145 
1983 P PMRC1 Tsukuba, Japan  700 
1984 P PSI-1  Villigen, Switzerland 4646 
1989 P  Dubna, Russia 318 
1989 P  Uppsala, Sweden 738 
1989 P  Clatterbridge, England 1584 
1990 P  Loma Linda, CA 11414 
1991 P  Nice, France 3129 
1991 P  Orsay, France 3766 
1993 P  iThemba, South Africa 486 
1993 P MPRI IN, USA 220 
1994 P UCSF CA, USA  920 
1994 Ion HIMAC Chiba, Japan 2867 
1995 P TRIUMF Canada 111 
1996 P PSI-2 Switzerland 262 
1997 Ion GSI Germany 316 
1998 P HMI Berlin, Germany 829 
1998 P NCC Kashiwa, Japan 462 
2001 P + ion HIBMC Hyogo, Japan 1099 + 131 
2001 P PMRC2 Tsukuba, Japan 930 
2001 P NPTC Boston, USA 2080 
2002 P INFN-LNS Catania, Italy 114 
2002 P  Wakasa, Japan 33 
2003 P  Shizuoka, Japan 410 
2004 P WPTC Zibo, China 270 
2006 P MD Anderson Houston, USA  114 
2006 P FPTI Jacksonville, FL, USA 15 
2007 P RPTC Munich, Germany  
2007 P + ion HIT Heidelberg, Germany  
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PARTICLE THERAPY FACILITIES COMMISSIONING, UNDER 
CONSTRUCTION – PLANNING STAGE 
 
 
YEAR Proton(p)/ 
Carbon (ion) 
Facility LOCATION  
2007/08 P PSI Villigen, Switzerland 
(OPTIS2/Gantry2) 
Near 
completion 
2007 P NCC Seoul, Korea  
2007 P + ion CNAO Italy Near 
completion 
2009 P UPenn USA  
2009 P WPE Essen, Germany  
2009? P iThemba Labs South Africa  
2009? P RPTC Koeln, Germany  
2010? P ICPO Orsay, France  
2010? P  Trento, Italy  
2011? Ion Gunma Univ Japan  
2011 P Northern Illinois 
PT Res Inst 
Chicago, IL, USA  
2011 P + ion PTC Marburg, Germany  
2011 P + ion ETOILE Lyon, France  
2011? P + ion Med-AUSTRON Austria  
 
More than 16 centres over 5 years: 11 in Europe, 5 in Germany - majority with ion 
beams . 
 
 
 
 
 
 
 
 
 
 
 
 . 
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Appendix II Principal Diseases Treated with Protons at Loma Linda Medical 
Center 
 
Brain and Spinal Cord 
• Arteriovenous Malformations – treatment of defects of the circulatory system 
• Isolated Brain Metastases – High radiation reduces symptoms 
• Pituitary Adenomas – Fractionated radiation over radiosurgery 
 
Base of Skull 
• Acoustic Neuromas – Benign tumours affecting hearing 
o Chordomas and Chondrosarcomas – Tumours of the brain stem, spinal cord or 
central nervous system 
• Meningiomas – Tumours treated in a few treatments 
 
Eye 
• Uveal Melanomas – Malignant tumours treated with protons to minimize eye 
removal need 
 
Head and Neck 
• Nasopharynx – Local carcinoma treatment via protons to reduce side effects 
• Oropharynx Cancer (locally advanced) – Dose localization to minimize healthy 
tissue damage 
 
Chest and Abdomen 
• Chordomas and Chondrosarcomas – Tumours of the brain stem, spinal cord or 
central nervous system 
• Early Lung cancer – Local treatment to minimize lung injury 
 
Pelvis 
• Prostate cancer – High dose, localized treatment for higher survival rate and 
minimum side effects 
 
Tumours in Children 
• Brain tumours – Highly individualized localized treatment options via protons 
• Orbital and Ocular Tumours – Proton treatment to prevent healthy lens and 
anterior chamber damage 
• Sarcomas of the base of the skull and spine – a variety of condition now treated in 
children. 
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 Appendix III Number of Patients treated with Carbon Ion Therapy at NIRS, Japan 
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Appendix IV  Evaluation of Cancer Types in ECM expected to benefit from Hadron 
Therapy 
 
 37
 Appendix V  Construction Staff 
 
   Hadron  Staff Construction  Costs 
       
Staff Member Cost/member Number Year 1 Year 2 Year 3 Year 4 
       
Project Director 300,000 1 150000 300000 300000 300000
Deputy 200000 1 200000 200000 200000 250000
Project Engineer 250000 1 250000 250000 250000 250000
       
Accelerator Staff       
Accelerator Head 200,000 1 100000 200000 200000 200000
Deputy 150,000 1 75000 150000 150000 150000
Accelerator Physicists 100,000 2 100000 200000 200000 200000
Head Electrical Engineer 150,000 1 75000 150000 150000 150000
Electrical Engineers 100,000 2 100000 200000 200000 200000
Head Mechanical 
Engineer 150,000 1 75000 150000 150000 150000
Mechanical Engineers 100,000 2 100000 200000 200000 200000
Technicians 100,000 4 200000 400000 400000 400000
Control Staff 120,000 6 360000 720000 720000 720000
       
Laboratory Staff       
Head treatment 500,000 1  500000 500000 500000
Deputy 200,000 1  150000 150000 150000
Software 120,000 4  480000 480000 480000
Technicians 100,000 3  400000 400000 400000
       
Safety Officer 100,000 1  100,000 100,000 100,000
       
Administration       
Business Manager 150000 1 75000 150000 150000 150000
Business Assistants 80000 3  80000 160000 240000
Receptionist 60000 1   60000 60000
OAS 80000 2  40000 80000 80000
       
Contact Staff 100000 10  1,000,000 1,000,000  
       
Totals  50 1860000 6020000 6200000 5330000
       
Grand Total      $19,410,000
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 Appendix VI - Committees 
 
Council 
 Internationally recognised scientists from Major Research Institutions 
 
Physics and Engineering Advisory Committee 
 International specialists in Accelerators and Associated Facilities 
 
International Medical and Therapy Advisory Committee 
 International Specialists in Hadron Therapy and Associated Sciences 
 
National Advisory Committee 
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